Global Hypereosinophilic Syndrome Market, By Treatment (Biological Therapy, Corticosteroid, Chemotherapy, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hypereosinophilic Syndrome Market Analysis and Size
The global hypereosinophilic syndrome market is expected to witness significant growth during the forecast period. high diagnostic rate and improvement in healthcare facilities are some of the impacting factors that drive the market growth. The expanding healthcare infrastructure in developing countries and the availability of generic medicine are some of the main factors driving the hypereosinophilic syndrome market during the forecast period. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in global hypereosinophilic syndrome market in the forecast period 2022-2029. The expected CAGR of global hypereosinophilic syndrome market is tend to be around 9% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hypereosinophilic syndrome is haematological disorders characterised by abnormally high concentrations of eosinophils leading to organ damage, mainly skin, lungs, heart, and gastrointestinal tract. Eosinophils are a type of white blood cells that is an essential component of blood that helps maintain the immune system. High count of eosinophils can indicate spectrum of distressing infectious diseases.
Hypereosinophilic Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Biological Therapy, Corticosteroid, Chemotherapy, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Mission Pharmacal Company (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Global Hypereosinophilic Syndrome Market Dynamics
Drivers
- Increasing Cases of Cancer
Increasing incidence of cancer is boosting the growth of the market. As per the reports of the American Cancers Society in 2018, around 1,735,350 new cases of cancer will be diagnosed, and approximately 609,640 cancer deaths are estimated in the U.S. in 2018. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rise in Autoimmune Disorders
As per the records of the America Autoimmune Related Disease Association (AARDA), around 50 million Americans suffered from autoimmune disorders back in 2017, and their incidence is still on the rise. Hence, it boosts the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of Awareness about the infection
The lack of awareness about this syndrome could curb the growth of the global hypereosinophilic syndrome market over a forecast period. Not much awareness about the syndrome leads to improper treatment thus restraining the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global hypereosinophilic syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypereosinophilic syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypereosinophilic Syndrome Market Scope
The global hypereosinophilic syndrome market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Biological Therapy
- Corticosteroid
- Chemotherapy
- Others
Route of Administration
- Oral
- Injectable
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypereosinophilic Syndrome Market Regional Analysis/Insights
The global hypereosinophilic syndrome market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global hypereosinophilic syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for hypereosinophilic syndrome market throughout the forecasted period due to leading leaders in research and development.
North America dominates the market due to the high demand for disease-specific treatment, rise in adoption of newer technologies, presence of refined healthcare expenditure, increased patient awareness level, and high prevalence of bleeding disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypereosinophilic Syndrome Market Share Analysis
The global hypereosinophilic syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypereosinophilic syndrome market.
Key players operating in the global hypereosinophilic syndrome market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- AbbVie Inc. (Ireland)
- Melinta Therapeutics, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Lupin (India)
- Mission Pharmacal Company (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-